EN DE
Watch Celemics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Celemics Inc (331920) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Celemics Inc stock KRW 5,937, price KRW 7,990, that is 25.7% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

CI Celemics Inc logo Thin data Nov 10, 2026

Celemics Inc

331920 · KQ
Expensive, weak quality

Our calculation puts a fair price 26% below what the stock costs today.

Low debt
Revenue last quarter +22% vs. a year ago.
Quality 42/100
Fair value 5,937 KRW · Overvalued
Weak Growth (revenue 5y +1.8 %/yr in KRW)
Loss-making · -194.8% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Celemics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

20,950 KRW 2,580 KRW Fair Value 5,937 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 2,580 KRW – 20,950 KRW · fair‑value band 4,453 KRW – 7,422 KRW · the 7,990 KRW price screens above the 5,937 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Celemics in your weekly email

Every Wednesday you see whether Celemics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Celemics, Inc. designs, manufactures, and distributes sequencing kits in South Korea.

Show moreShow less

The company offers whole exome sequencing panels; NGS target enrichment panels; customized and ready-to-use enrichment panels; and modular accessories, including library preparation kits, double standard Cdna synthesis, hybridization enhancer, celan-up and streptavidin beads, CeleNM beads, and polymerase.

It also provides celemics analysis, whole exome sequencing, customized NGS panels, sequencing, bioinformatics, biopharma, and custom NGS assay development services.

Its products are used in oncology, liquid biopsy, biopharma solutions, inherited diseases, pharmacogenomics, virus research, agrigenomics, RNA sequencing, epigenetics, metagenomic sequencing, antibody discovery, and bioinformatics applications.

The company was founded in 2010 and is headquartered in Seoul, South Korea.

Stock analysis

Celemics Inc (331920) currently trades at 7,990 KRW, while our estimate is 5,937 KRW, 26% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 4,453 KRW (bear) to 7,422 KRW (bull), the price of 7,990 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Celemics Inc reported revenue of 5.8B KRW in FY2025 versus 8.1B KRW in FY2021, a compound −8.1%/yr. Reported net income was −4.0B KRW in FY2025.

Key figures

Market cap 89.3B KRW (≈ $67.0M) Micro · P/S ratio 19.8 · EPS (TTM) −909.35 KRW · Net margin −70.0% · Return on equity −38.8% · Return on assets (EBIT) −20.0% (5-year average) · Operating margin −67.2% · Revenue (TTM) 5.2B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 56% below its 52-week high and 210% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −26%, 331920 screens richer than that median.

Fair Value

Bear 4,453 KRW Fair Value 5,937 KRW Bull 7,422 KRW
Price 7,990 KRW · Downside -25.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 11
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 86
Debt, balance sheet and risk of trouble
Investment 81
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 67
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 9/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−14.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−92.9% (2020) → −57.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

331920 screens overvalued: fair value 26% below the price. Compare with Abbott Laboratories, →

Compare Celemics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −25.7% · Below median
Profitability
Return on assets −16.5% · Below median
Net margin (12 months) −194.8% · Bottom 25%
Operating margin (12 months) −67.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 22.4% · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.88× · Pricier than median
P/S (12 months) 17.12× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs 331920
DexCom, Inc DXCM $79.92 $89.18 +12% vs 331920
Stryker Corporation SYK $324.29 $358.30 +10% vs 331920
STERIS plc STE $257.12 $279.53 +9% vs 331920
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs 331920
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs 331920
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs 331920
Abbott Laboratories, ABT $110.46 $75.28 −32% vs 331920
Medtronic plc MDT $101.59 $65.61 −35% vs 331920
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs 331920

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Celemics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Celemics Inc Fair Value". https://www.fairvalue-calculator.com/stock/331920

Frequently asked questions

Is Celemics Inc (331920) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 5,937 KRW versus a price of 7,990 KRW, about 26% lower (overvalued).
What is the fair value of 331920?
Our estimate for Celemics Inc is 5,937 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 7,990 KRW.
What is the quality score of 331920?
Celemics Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Celemics Inc (331920)?
Our calculated price target is the estimate of 5,937 KRW (as of Nov 10, 2026). Cautious scenario 4,453 KRW, optimistic scenario 7,422 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Celemics Inc stock forecast for 2026?
Our estimate puts fair value at 5,937 KRW, about 26% lower versus a price of 7,990 KRW (overvalued). Cautious scenario 4,453 KRW, optimistic scenario 7,422 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Celemics Inc (331920)?
Celemics Inc reported trailing-twelve-month revenue of about 5.2B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Celemics Inc (331920)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Celemics Inc it is 5,937 KRW per share (as of Nov 10, 2026), against a price of 7,990 KRW.
Is Celemics Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 331920 trades above its calculated fair value: price 7,990 KRW, fair value 5,937 KRW, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 331920?
No. The price is what the market pays today (7,990 KRW); the fair value is what the company's own numbers justify (5,937 KRW). For Celemics Inc the two are 2,053 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Celemics Inc worth?
The market values Celemics Inc at about 89.3B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 7,990 KRW; our models calculate a fair value of 5,937 KRW per share.
What do the bullish and bearish scenarios say about 331920?
Our models span a range for Celemics Inc: cautious scenario 4,453 KRW, base 5,937 KRW, optimistic 7,422 KRW per share (as of Nov 10, 2026, price 7,990 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Celemics Inc (331920)?
Balance-sheet figures for Celemics Inc (as of Nov 10, 2026): return on equity −38.8%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 331920 from its 52-week high?
Celemics Inc trades at 7,990 KRW, about 56% below its 52-week high of 18,200 KRW and 210% above the low of 2,580 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 5,937 KRW is for.
Which stocks are comparable to Celemics Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Celemics Inc stock attractive at the current price?
The data as of Nov 10, 2026: price 7,990 KRW, calculated fair value 5,937 KRW (−26%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Celemics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Celemics Inc (331920)?
The closing price on Nov 10, 2026 was 7,990 KRW. Our estimate is 5,937 KRW, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Celemics Inc right now?
The price sits above even our optimistic bull case (7,422 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Celemics Inc

How large is the market capitalisation of Celemics Inc (331920)?
The market capitalisation of Celemics Inc is 89.3B KRW (≈ $67.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Celemics Inc (331920)?
The price-to-sales ratio of Celemics Inc is 19.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Celemics Inc (331920)?
Earnings per share at Celemics Inc are −909.35 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Celemics Inc (331920)?
The net margin of Celemics Inc is −70.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Celemics Inc (331920)?
The return on equity (ROE) of Celemics Inc is −38.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Celemics Inc (331920)?
On an EBIT basis the return on assets of Celemics Inc is −20.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Celemics Inc (331920)?
The operating margin of Celemics Inc is −67.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Celemics Inc (331920)?
Revenue at Celemics Inc is growing +22.4% versus a year earlier (3y avg −12.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Celemics Inc (331920) generate?
The free cash flow of Celemics Inc is −3.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Celemics Inc in the live analysis

One click puts Celemics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.